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Malaria induces potent activation and expansion of the V9V2 subpopulation of T cells, which inhibit the Plasmodium fal-
ciparum blood cycle through soluble cytotoxic mediators, abrogating merozoite invasion capacity. Intraerythrocytic stages effi-
ciently trigger V9V2 T-cell activation and degranulation through poorly understood mechanisms. P. falciparum blood-stage
extracts are known to contain phosphoantigens able to stimulate V9V2 T cells, but how these are presented by intact infected
red blood cells (iRBCs) remains elusive. Here we show that, unlike activation by phosphoantigen-expressing cells, V9V2 T-cell
activation by intact iRBCs is independent of butyrophilin expression by the iRBC, and contact with an intact iRBC is not re-
quired. Moreover, blood-stage culture supernatants proved to be as potent activators of V9V2 T cells as iRBCs. Bioactivity in
the microenvironment is attributable to phosphoantigens, as it is dependent on the parasite DOXP pathway, on V9V2 TCR
signaling, and on butyrophilin expression by V9V2 T cells. Kinetic studies showed that the phosphoantigens were released at
the end of the intraerythrocytic cycle at the time of parasite egress. We document exquisite sensitivity of V9V2 T cells, which
respond to a few thousand parasites. These data unravel a novel framework, whereby release of phosphoantigens into the extra-
cellular milieu by sequestered parasites likely promotes activation of distant V9V2 T cells that in turn exert remote antipara-
sitic functions.
In humans and nonhuman primates, the main peripheral bloodT-cell subset expresses the V9 and V2 T-cell receptor
(TCR) chains. This V9V2 T-cell subset accounts for 1 to 10% of
total blood T lymphocytes and is expanded in patients upon in-
fection by pathogens such as Plasmodium falciparum (1–5) or My-
cobacterium tuberculosis (6) and in patients with lymphoid malig-
nancies (7). In malaria patients, this expansion may play a dual
role, both promoting pathology (3, 5) and contributing to the
control of parasite density. Indeed, V9V2 T cells efficiently
limit in vitro P. falciparum expansion by granulysin-dependent
cytotoxicity (1, 8–10). In malaria patients, high levels of granuly-
sin-expressing V9V2 T cells correlate with their ex vivo parasite-
specific degranulation capacity, and elevated granulysin concen-
tration in plasma suggests significant discharge during acute P.
falciparum malaria (1). As a step toward a better understanding of
how V9V2 T cells target parasites, we recently showed that the
antiparasitic activity of V9V2 T cells targets the extracellular
merozoites (1). The intraerythrocytic developmental stages,
which appear insensitive to the antiparasitic effect (1), seem to
potently trigger V9V2 T-cell activation and degranulation (1,
11–14). However, how precisely and which intraerythrocytic de-
velopmental stages activate V9V2 T cells still is unclear.
V9V2 T cells are activated by so-called phosphoantigens,
which are nonpeptidic intermediate metabolites of the isoprenoid
production pathway (15; recently reviewed in reference 16). The
natural phosphoantigen (E)-4-hydroxy-3-methyl-but-enyl-pyro-
phosphate (HMBPP) is produced by the DOXP pathway and is
1,000 times more potent for specifically activating V9V2 T cells
than the isopentenyl-pyrophosphate (IPP) molecule, which is
produced by both the DOXP pathway and the mevalonate path-
way (17, 18). Apicomplexa and, notably, Plasmodium spp. do not
possess the mevalonate pathway and use the DOXP pathway to
produce isoprenoids (19). Although it has been shown that
V9V2 T-cell activation by P. falciparum extracts is abrogated by
apyrase treatment (12), the involvement of the parasitic DOXP
pathway has never been formally proven, and the potency of the
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bioactivity of parasitic phosphoantigens on V9V2 T cells has
never been assessed.
In the case of tumor cells, it is well established that cell-to-cell
contact is required for V9V2 T-cell activation, and, like cyto-
toxicT cells, their activation may be triggered by the formation
of a cytotoxic synapse during contact with an activating tumor
target cell (20). Recent reports demonstrated a mandatory role for
a B7-related butyrophilin (CD277/BTN3A) for the phosphoanti-
gen-dependent activation of V9V2 T cells by tumor targets or
mycobacterium-infected cells (21–24). One of the proposed mod-
els suggests that V9V2 T cells recognize BTN3A modifications
induced by binding the phosphoantigens produced inside the tar-
get cells (22). However, phosphoantigens also can be released into
the supernatant of microorganisms or infected cell cultures. Fur-
thermore, soluble phosphoantigens can be pulsed onto the surface
of noninfected presenting cells (25), which stimulate V9V2 T
cells in a contact-dependent manner. This suggests that V9V2 T
cells can be activated by soluble phosphoantigens at a distance
from the producing cell.
In the case of P. falciparum, numerous studies have reported
stimulation of V9V2 T cells by schizont extracts/infected red
blood cell (iRBC) lysates (3, 11, 12, 14, 26), culture supernatants
(26–29), and/or intact iRBCs cocultivated with V9V2 T cells (1,
5, 14, 30), suggesting that V9V2 T-cell contact with iRBC is
dispensable. However, at this point, how P. falciparum intracellu-
lar stages activate V9V2 T cells is unknown.
To address these issues and to gain novel insights on V9V2
T-cell activation by P. falciparum, here we explored the expression
of BTN3A by iRBC, the timing of phosphoantigen release by
iRBC, and the involvement of the parasite DOXP pathway in
phosphoantigen production, and we quantified the P. falciparum
bioactivity for V9V2 T cells.
MATERIALS AND METHODS
P. falciparum culture. FCR3 parasites were cultured in O red blood cells
(RBCs) (Etablissement Français du Sang-EFS-Aquitaine, France) in com-
plete parasite medium (CPM; RPMI 1640 supplemented with 10% hu-
man serum, gentamicin, glutamine, and hypoxanthine) and were regu-
larly tested for the absence ofMycoplasma contamination (1). Parasitemia
was assessed by hydroethidine staining (31) or examination of Giemsa-
stained smears. Parasite cultures were synchronized by sorbitol (32)
and/or heparin treatment (33). When required, midstage schizonts
(around 38 to 40 h postinvasion [hpi]) were purified by gel flotation on
gelofusin to80% parasitemia (31).
Generation of V9V2 T-cell lines. Short-term lines (T-cell lines)
were generated from healthy donor peripheral blood mononuclear cells
(PBMCs; EFS Aquitaine, France) as previously described (1). Briefly,
PBMCs were stimulated with 400 nM bromohydrin pyrophosphate
(BrHPP) (IPH1101; Innate Pharma) in complete medium (RPMI 1640
supplemented with 10% decomplemented fetal calf serum, glutamine,
and antibiotics) in the presence of 300 UI/ml interleukin-2 (IL-2). After
20 days, V9V2 T-cell purity was evaluated by flow cytometry (FACS
Fortessa; BD Biosciences). T-cell lines were used when the percentage
of V2 CD3 cells was 80%, unless indicated otherwise. For each
experiment, two T-cell lines, freshly generated in parallel from two
distinct donors, were used.
BTN3A staining. PBMCs, T-cell lines, purified P. falciparum cul-
tures and uninfected red blood cells (uiRBCs) were stained with 15g/ml
anti-butyrophillin 3 (BTN3A) antibody (clone 20.1; kind gift from E.
Scotet, Nantes, France) for 45 min at room temperature. Cells were
washed once and stained with fluorescein isothiocyanate (FITC)-coupled
goat anti-mouse antibody (Beckman-Coulter) for 1 h at room tempera-
ture. After washing, PBMCs and T-cell lines also were stained with
anti-CD3-phycoerythrin (PE) antibody (Becton-Dickinson), and iRBCs
were stained with hydroethidine (5 g/ml) to discriminate iRBCs from
uiRBCs. Surface marker expression was assessed by flow cytometry.
CD107a degranulation assay. The CD107a degranulation assay was
performed as described previously (1). Briefly, 105 cells of T-cell lines
starved overnight of interleukin-2 (IL-2) or freshly collected PBMCs were
incubated in the presence of stimulant and anti-CD107a-PE antibody
(BD Bioscience) for 4 h. Cells were collected, washed, labeled with anti-
V2-FITC antibody (Beckman Coulter), and analyzed by flow cytometry.
For transwell experiments, cell culture inserts (0.4-m polycarbonate
membrane; the Transwell system; Nunc, Roskilde, Denmark) were used
by following the manufacturer’s recommendations, with T cells seeded
in the bottom of the wells in the presence of anti-CD107a-PE antibody
and midstage schizonts (38 to 40 hpi) in the upper chamber. For antibody
blocking experiments, T cells were preincubated for 1 h with anti-V2
(clone immu389; Beckman Coulter), anti-BTN3A (clone 103.2; kind gift
from D. Olive [21]), or anti-NKG2D (clone 149810; R&D Systems) anti-
body before stimulation as described previously (1).
Preparation of iRBC supernatants. Synchronized midstage schizont
cultures (38 to 40 hpi) were washed and adjusted to 5% hematocrit in
CPM. Culture supernatants (G, J, K, L, M, and S) were prepared from
independent parasite cultures and collected 4 h later from a 4% para-
sitemia culture. Each culture supernatant was tested on at least two dif-
ferent T-cell lines, and at least two different supernatants were used in
each assay. Rupture supernatants were collected from cultures at 1.5%
parasitemia, when rupture was complete and reinvasion had occurred.
Parasite stages were estimated from microscopic examination of Giemsa-
stained smears. All of the collected supernatants were spun down at 870	
g for 5 min, filtered through a 0.22-m Millipore filter, and frozen until
use. As a control, supernatant from uiRBCs cultivated in parallel was
collected using the same protocol. When indicated, supernatants were
ultracentrifuged in a Beckman Optima L-100XP centrifuge in a 90Ti rotor
at 197,000	 g for 3 h at 4°C. For pyrophosphatase treatment, we used 0.2
U/ml potato apyrase (Apy) (Sigma-Aldrich) for 1 h as described previ-
ously (34), followed by filtration using a 3-kDa-cutoff Centricon filter
(Amicon) according to the manufacturer’s instructions. Supernatant ac-
tivity was tested by CD107a assay.
Fosmidomycin treatment. Young trophozoite iRBC cultures (20 hpi)
were adjusted to 4% parasitemia, 5% hematocrit in CPM and incubated
for 21 h with serial dilutions of fosmidomycin with or without the addi-
tion of 1 M farnesyl pyrophosphate (both from Sigma-Aldrich). Dupli-
cate supernatants of treated parasites were frozen until use. T-cell lines
were treated similarly. In order to assess the effect of fosmidomycin on
iRBC viability after 21 h of incubation, iRBC cultures were diluted to 1%
parasitemia and 1% hematocrit and allowed to reinvade in fresh CPM.
Cycle progression was assessed by Giemsa staining, and parasitemia was
determined by hydroethidine staining as described above.
Kinetics of phosphoantigen andPfHRP2 release.Three independent
cultures (A, B, and C) of synchronized iRBCs (14 hpi) were washed and
adjusted to 1% parasitemia and 5% hematocrit in CPM and dispensed in
24-well plates. Cultures were unfed during the time of study. Supernatants
from duplicate wells were collected at different time points, filtered
through a 0.22-m filter, and frozen until use. Supernatants from uiRBCs
served as controls. Thawed supernatants were tested in duplicate for phos-
phoantigen bioactivity on two independent T-cell lines. iRBC rupture
was assessed by monitoring parasite developmental stages using Giemsa-
stained blood smears.P. falciparumhistidine-rich protein 2 (PfHRP2) was
measured in supernatants using a commercial enzyme-linked immu-
nosorbent assay (ELISA) by following the manufacturer’s instructions
(Malaria Ag Celisa; Cellabs, Sydney, Australia).
Treatment with the apicomplexan cGMP-dependent protein kinase
inhibitor compound C2. Synchronized schizont cultures (around 40 to 44
hpi) were washed once with RPMI, adjusted to 1% parasitemia and 5% he-
matocrit, and resuspended in CPM containing 2M compound 2, which was
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4-[7-[(dimethylamino)methyl]-2-(4-fluorphenyl)imidazo[1,2-a] pyridin-
3-yl]pyrimidin-2-amine, or its vehicle, dimethyl sulfoxide (DMSO) (35).
iRBC supernatants were collected at various time points.
Statistical analysis. Statistical tests used are indicated in the figure
legends when applied. When shown, error bars correspond to means 

standard deviations (SD).
RESULTS
Plasmodium falciparum-infected red blood cells do not express
butyrophilin 3 and activate V9V2 T cells in the absence of
contact. We first asked whether P. falciparum iRBCs could acti-
vate V9V2 T cells by a mechanism similar to that of cancer cells,
through BTN3A binding of intracellular phosphoantigens (21–
24). Using flow cytometry we found that, contrary to T cells, nei-
ther uninfected RBC (uiRBC) nor iRBC expressed BTN3A (Fig.
1A). This suggests that iRBCs activate V9V2 T cells through an
alternative mechanism, involving either another phosphoantigen
presentation molecule on the iRBC surface or through recogni-
tion of phosphoantigens released by iRBCs into the microenvi-
ronment.
To examine whether contact of iRBCs with V9V2 T cells was
mandatory for activation, V9V2 short-term lines (T-cell
lines) were coincubated with iRBCs with or without physical sep-
aration by a transwell insert, and their activation was monitored
using a CD107a degranulation assay (1). The gating strategy is
illustrated in Fig. 1B, showing, as expected, that 87%, 25%, and
28% of V9V2 T cells activated with HMBPP, Daudi cells, and
iRBC, respectively, expressed the CD107a marker of degranula-
tion. Separation by a 0.4-m transwell membrane abrogated
V9V2 T-cell activation by the Daudi cell line, which is known to
require cell-cell contact, and did not alter the response to soluble
HMBPP. Interestingly, physical separation by the transwell did
not abrogate or alter V9V2 T-cell reactivity to iRBCs (Fig. 1C;
also see Fig. S1A in the supplemental material). This indicates that
soluble mediators, released by mature iRBCs and diffusing freely
across the 0.4-m transwell membrane, activate V9V2 T cells in
the absence of contact with iRBCs. This was confirmed by time-
lapse confocal microscopy (see Fig. S1B), where almost all
V9V2 T cells formed long-lived conjugates with Daudi cells,
while iRBC-V9V2 conjugates were scarcely observed. Consis-
tent with this, we did not detect conjugates between V9V2 T
cells and iRBCs by flow cytometry. Altogether, these data suggest
that triggering of V9V2 T-cell activation by iRBCs relies on
soluble mediators released in the microenvironment.
Molecules released in iRBC supernatant activate V9V2 T
cells in a TCR- and BTN3A-dependent manner and have char-
acteristics of phosphoantigens. P. falciparum is known to pro-
duce HMBPP through the DOXP pathway, and iRBC extract has
been shown to contain HMBPP; however, little is known about
the release of phosphoantigens in iRBC culture supernatants. To
gain insight on this aspect, we generated culture supernatants
from iRBCs and examined their ability to activate V9V2 T cells.
Consistent with transwell experiments, the iRBC supernatant in-
duced V9V2 T-cell activation from fresh PBMCs in the same
range as intact iRBCs (Fig. 2A, left). This shows that parasite su-
pernatant activation of V9V2 T cells did not require their prior
in vitro priming, expansion, or selection. Supernatants also in-
duced degranulation of T-cell lines in a dose-dependent man-
ner (Fig. 2A, right). Moreover, ultracentrifugation of iRBC super-
natant did not alter its capacity to activate V9V2 T cells (Fig.
2B), indicating that the activating mediators are not carried by
exosome-like vesicles released by iRBCs (recently described by
Regev-Rudzki et al. [36]) that can cross the 0.4-m transwell
membrane.
Thus, we investigated whether the activating molecules re-
leased in the iRBC supernatant had the reported chemical charac-
teristics of phosphoantigens (12). Supernatants ultrafiltered using
3-kDa-cutoff filters efficiently activated V9V2 T cells but lost
this activity after a prior treatment with apyrase, similar to the
prototypic phosphoantigen HMBPP (Fig. 2C). Apyrase treatment
did not affect V9V2 T cells, as activation induced by an anti-
CD3 antibody was insensitive to the addition of apyrase-treated
supernatants. Therefore, the activating molecules released in the
iRBC supernatant have a molecular mass lower than 3 kDa and are
terminally pyrophosphorylated. Furthermore, activation of
V9V2 T cells by iRBC supernatant was prevented using anti-
V2 blocking antibody in a dose-dependent manner, as was the
activation by HMBPP (Fig. 2D). This indicates that iRBC super-
natant, like HMBPP, stimulates V9V2 T cells in a TCR-depen-
dent manner. NKG2D, an activating receptor expressed by
V9V2 T cells, also could be involved in these mechanisms.
However, including an anti-NKG2D blocking antibody in the ac-
tivation test had no effect on V9V2 T-cell activation. T-cell
FIG 1 Plasmodium falciparum-infected RBC do not express butyrophilin 3
and activate V9V2 T cells without contact. (A) Plasmodium falciparum-
infected (iRBCs) or uninfected red blood cells (uiRBCs) were incubated with
anti-butyrophilin3 (BTN3A) antibody (black line) or with an isotypic control
(light gray) and analyzed by flow cytometry. BTN3A expression in CD3
PBMC also was analyzed. Shown are data of BTN3 labeling from one repre-
sentative experiment out of three. (B) Gating strategy for CD107a degranula-
tion test. V9V2 short-term lines (T-cell lines) were incubated with stim-
ulants (medium, HMBPP, Daudi cells, or iRBC at a 10:1 target-to-effector
ratio) and PE-labeled anti-CD107a antibody for 4 h, washed, and subsequently
incubated with FITC-labeled anti-V2 antibody. Degranulated cells are iden-
tified by flow cytometry as CD107a-positive cells within the V2 population.
(C) Stimulants (100 nM HMBPP, 200 nM BrHPP) or target cells (iRBCs,
uiRBCs, or Daudi cells at the indicated target/effector ratios) were either incu-
bated for 4 h with V9V2 T cells or cultured in the upper chamber of the
0.4-m polycarbonate transwell device. V9V2 T-cell degranulation was fur-
ther assessed by CD107a assay after 4 h of incubation in contact with (gray
bars) or physically separated from (black bars) stimulants as indicated. Shown
are the results from one representative T-cell line (T-cell line 168) out of
4 (complete data are in Fig. S1 in the supplemental material). Midstage schi-
zonts (38 to 40 hpi) were used as iRBCs.
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lines expressed BTN3A after expansion (Fig. 2E, left). Activation
of V9V2 T cells by phosphoantigens has been shown to be de-
pendent on BTN3A expression by V9V2 T cells themselves
(21). In line with this, V9V2 T-cell activation by iRBC superna-
tant was abrogated using neutralizing anti-BTN3A antibody
(clone 103.2) (Fig. 2E, right). Thus, the activating molecule(s)
released in the culture supernatant have the properties of phos-
phoantigens.
The activatingmolecules released by iRBC are intermediates
of theDOXPpathway. In order to assess the contribution of the
parasites’ DOXP pathway to the production of iRBC-released
bioactive molecules, we incubated iRBCs in the presence of
fosmidomycin, which inhibits DOXP reductase, the first en-
zyme of this pathway (37) (Fig. 3A). V9V2 T-cell activation
by iRBC culture supernatants was efficiently reduced by fos-
midomycin in a dose-dependent manner (Fig. 3B, black line).
However, as high doses of fosmidomycin specifically inhibit
parasite cycle progression (Fig. 3C), the decrease of V9V2
T-cell activation might merely reflect a quantitative decrease of
parasite maturation and a correlative diminution of phospho-
antigen production. In order to circumvent this putative bias,
fosmidomycin-treated parasite cultures were complemented
with exogenous farnesyl pyrophosphate (FPP), which is pro-
duced downstream from the prototypical phosphoantigens
HMBPP and IPP (Fig. 3A). In order to determine the optimum
dose of FPP able to rescue parasitemia, we monitored the
iRBC-treated cultures up to 42 h posttreatment and selected a
dose of 1 M FPP (see Fig. S2A in the supplemental material).
While 1 M FPP effectively restored the parasite cell cycle pro-
gression in the presence of up to 5 M fosmidomycin for 21 h
(Fig. 3C, gray line), it did not restore the V9V2 T-cell acti-
vation capacity of the fosmidomycin-treated culture superna-
tants (Fig. 3B, gray line). Of note, neither fosmidomycin nor
FPP at the concentrations used affected V9V2 T-cell activa-
FIG 2 V9V2 T-cell activation is mediated by soluble phosphoantigen(s) in a TCR-dependent manner. The reactivity of V9V2 T cells toward iRBC culture
supernatants (iRBC-SNs) collected from different parasite cultures (M, J, K, L, and S) at 4% parasitemia was assayed using the CD107a degranulation test. (A)
Reactivity of V9V2 T cells from fresh PBMCs from 5 malaria-naive donors to intact iRBCs or uiRBCs at the indicated ratios was compared to the reactivity to
the corresponding culture supernatants (left) (statistical significance is calculated using one-way analysis of variance [ANOVA]; **, P 0.01; ***, P 0.0001).
Serial 2-fold dilutions of iRBC-SN J were assayed on V9V2 short-term lines (T-cell lines). (Right) Means
 SD from duplicates obtained from a represen-
tative experiment using one (T-cell line 226) out of two independently generatedT-cell lines. (B) Reactivity ofT-cell lines to iRBC-SN G was tested before
(UCF) and after (UCF) ultracentrifugation at 197,000 	 g on two T-cell lines (depicted are representative data obtained with T-cell line 151). (C)
V9V2 T-cell degranulation was measured after incubation with medium alone, HMBPP (100 nM), and iRBC-SNs J and L and were left untreated (black bars)
or treated (gray bars) with 0.2 U/ml apyrase at 37°C for 1 h, followed by 3-kDa-cutoff ultrafiltration (Centricon filter). Undiluted iRBC-SNs J and L were tested
on T-cell lines. Anti-CD3 antibody was used as a phosphatase-insensitive activation control. Data shown are means from duplicates 
 SD obtained from a
representative experiment using one (T-cell line 244) out of two independently generated lines. (D) V9V2 T cells were preincubated with blocking
antibodies against V2 or NKG2D at concentrations indicated in the caption before activation with either HMBPP (5 nM) or iRBC-SNs K and L. As a negative
control, supernatants from uninfected RBC (uiRBC-SNs) were collected and tested in parallel on two independent T-cell lines (shown is representative
T-cell line 227). (E) Expression of BTN3A was assessed on T-cell lines after 20 days of expansion (left). V9V2 T cells then were preincubated with either
1 g/ml anti-V2 antibody or 1 g/ml anti-NKG2D antibody or anti-BTN3A blocking antibody at the concentrations indicated before stimulation with either
HMBPP (5 nM) or iRBC-SNs L and S (right). Shown are results obtained using representative T-cell line 387 (out of 3).
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tion by HMBPP (see Fig. S2B). These results clearly demon-
strate the obligatory link between phosphoantigen production
by the parasite and V9V2 activation and indicate that the
V9V2 activators are produced upstream from FPP and
downstream from DOXP in the DOXP pathway.
V9V2-stimulating molecules are released in the culture
supernatant upon schizont rupture. The results described above
were obtained with iRBC culture supernatants collected from syn-
chronized cultures containing mostly mature stages (38 to 40 hpi)
of the parasite. To investigate the kinetics of activator molecule
release during blood-stage development, supernatants were col-
lected at different time points after invasion and their bioactivity
was tested on two T-cell lines using the CD107a assay (Fig. 4A).
The timing of iRBC schizont rupture was evaluated by monitoring
in parallel the release of HRP2 into the iRBC supernatants, which
occurs at the time of parasite egress (38). Bioactivity in the super-
natants raised abruptly around 40 hpi and reached a plateau by 50
hpi. Comparable activation kinetic profiles were observed for the
two T-cell lines, although maximal CD107a reactivity was 20%
forT-cell line 232 and more than 30% forT-cell line 233. The
kinetics of HRP2 release were superimposable on those of bioac-
tivity release and were consistent with schizont rupture monitored
using Giemsa-stained smears, which showed reinvasion starting at
approximatively 40 hpi and being essentially complete by 50 hpi.
Altogether, this indicated that the V9V2 activators were re-
leased concomitantly with HRP2, at the very end of the intraeryth-
rocytic cycle, most likely upon parasite egress.
To confirm this conclusion, we blocked parasite egress using
compound 2 (C2), a specific inhibitor of the parasite cGMP-
dependent protein kinase G that regulates parasite egress (35).
After checking that the C2 used did not affect V9V2 T-cell
activation by HMBPP, we tested the ability of supernatants
from C2-treated cultures to activate V9V2 T cells (Fig. 4B).
Late intraerythrocytic developmental stages were treated with
C2 for up to 10 h, and the culture supernatants collected at
different time points were tested for HRP2 and V9V2 T-cell
activation capability. We performed experiments with para-
sites at approximately 44 hpi (Fig. 4B, top) or parasites at ap-
proximately 42 hpi to avoid early schizont rupture events (Fig.
4B, bottom). Under both conditions, blocking schizont rup-
ture by C2 prevented the release of HRP2 into the culture su-
pernatant, as expected, and strongly decreased their bioactivity
(Fig. 4B), leading to a C2-induced plateau, contrasting with the
sustained increase in the mock-treated culture. C2 treatment
was reversible, as parasites resumed egress and simultaneously
discharged HRP2 and phosphoantigens into the supernatants
after C2 withdrawal (Fig. 4C). There was an almost quantitative
recovery of the HRP2 and phosphoantigen bioactivity in the
C2-treated culture supernatant after washing out C2 and fur-
ther culturing the parasites in the absence of C2. Altogether,
these data led to the conclusion that the bulk of the activator
molecule content is released upon schizont rupture, although
we cannot exclude leaking of some bioactivity due to increased
permeability of iRBCs at the latest stages of schizogony (39).
Quantification of phosphoantigen bioactivity. Due to insuf-
ficient sensitivity, we were not able to directly measure phos-
phoantigen concentrations in the supernatants by standard
techniques (40). Therefore, we quantified bioactivity in iRBC su-
pernatants using the CD107a assay with two different T-cell
lines. We expressed bioactivity as HMBPP equivalents using a
calibration curve of V9V2 T-cell activation obtained with
HMBPP. Interestingly, the two T-cell lines prepared freshly for
this experiment had different dose-response profiles from that for
HMBPP (Fig. 5A). T-cell line 354 was exquisitely responsive,
with a maximal degranulation plateauing at concentrations above
0.39 nM HMBPP and with a calculated 50% maximal response
concentration (EC50) of 0.005 nM. T-cell line 355 was less re-
sponsive, with a calculated EC50 of 0.571 nM HMBPP and a re-
sponse threshold of 0.012 nM. The bioactivity of supernatants J, K,
and L, collected from late schizont cultures (previously used in
experiments shown in Fig. 2), was fitted to these dose-response
curves. J, K, and L bioactivities were estimated at 0.029, 0.044, and
0.072 nM HMBPP equivalents, respectively, using T-cell line
354, and at 0.042, 0.063, and 0.084 nM HMBPP equivalents, re-
FIG 3 DOXP pathway inhibition abrogates activation of V9V2 T cells by iRBC-SN. (A) Simplified representation of the steps in the DOXP pathway relevant
to our experimental protocol. G3P, glutaraldehyde 3 phosphate; DOXP, 1-deoxy-D-xylulose 5-phosphate; MEP, 2-C-methyl-D-erythritol 4-phosphate; HMBPP,
(E)-4-hydroxy-3-methyl-but-2-enyl pyrophosphate; IPP, isopentenyl pyrophosphate; DMAPP, dimethylallyl pyrophosphate; FPP, farnesyl pyrophosphate; exo.
FPP, exogenous FPP. Note that between MEP and HMBPP, several steps have been skipped. Endogenous products are in boldface characters. (B) V9V2 T-cell
reactivity was tested toward iRBC-SNs collected from iRBC cultures treated for 21 h with fosmidomycin in the presence or absence of 1M FPP. Data shown are
means
 SD of duplicates obtained from a representative experiment using T-cell line 266. (C) Effect of fosmidomycin treatment and exogenous FPP (1M)
addition on parasite culture progression. IRBC cultures were treated during 21 h with fosmidomycin, with or without 1M FPP. Parasitemia after reinvasion was
evaluated in triplicate wells. Controls in CPM alone without fosmidomycin are shown on the left.
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spectively, using T-cell line 355. This outlined a similar ability
to detect phosphoantigens for both T-cell lines, despite differ-
ing sensitivity and threshold responses.
To evaluate the overall parasite bioactivity, we collected the
rupture supernatant from a culture in which schizont rupture,
parasite egress, and parasite invasion had proceeded to comple-
tion. Bioactivity of this rupture supernatant was titrated with the
same two 354 and 355 T-cell lines and found to be 0.100 nM
and 0.192 nM, respectively (Fig. 5B). This indicated that 80	 104
ruptured schizont iRBCs produce roughly 2.6 to 5.2 pg HMBPP
equivalents, i.e., 0.003 to 0.006 fg per iRBC. Altogether, these re-
sults show that V9V2 T cells are extremely sensitive to trace
amounts of phosphoantigens.
DISCUSSION
In this paper, we clarify how V9V2 T cells are activated by
blood-stage malaria parasites. We show that iRBC-V9V2 T-cell
contact is dispensable, although we cannot formally exclude a pos-
sible interaction with merozoites. This is consistent with the ab-
sence of BTN3A on the iRBC surface, and that molecules with the
characteristics of phosphoantigens, the V9V2 T-cell-activating
moieties, are produced as soluble molecules from the DOXP path-
way and released mostly at the time of P. falciparum erythrocytic
egress. V9V2 T cells are shown to be exquisitely sensitive to
phosphoantigen stimulation, although with a substantial variabil-
ity among donors. The estimated parasite bioactivity and the low
threshold of V9V2 T-cell activation are compatible with a dis-
tant activation of V9V2 T cells by phosphoantigens released in
the blood during malarial infection.
As BTN3A is not expressed onto iRBCs, phosphoantigens can-
not be presented to V9V2 T cells by this molecule by the iRBCs,
unlike cancer cells (21–24). The potent activation noted by soluble
molecules released in the culture supernatant by iRBCs indicates
that presentation by the iRBC itself is fully dispensable. Ultracen-
trifugation ruled out the possibility of presentation by mi-
crovesicles (36), and efficacy of BTN3A blocking on V9V2 T-
cell activation suggested an autopresentation of the captured
parasite-derived activator molecules by the V9V2 T cells that
express BTN3A (25, 41). Thus, our overall results showed that the
FIG 4 Phosphoantigens are released during iRBC rupture. (A) Synchronized
parasites from 3 independent cultures (A, B, and C) at 1% parasitemia were
cultured in CPM for 62 h, and iRBC supernatants were collected at the indi-
cated time points (hours postinvasion [hpi]) across the parasite developmen-
tal cycle (time zero corresponds to parasitic invasion). The phosphoantigen
bioactivity in the various iRBC-SNs was assessed on two independent T-cell
lines (232 and 233) using CD107a surface expression. HRP2 concentration in
the iRBC-SNs was determined by ELISA. Data show the means 
 SD from
CD107a expression induced by the three independent culture SNs (A, B, and
C) and their means
 SD for HRP2 content at each time point. (B) Synchro-
nized iRBC cultures (1% parasitemia) were treated with compound 2 (C2) or
a control (DMSO) at the time indicated by the arrow, and supernatants were
collected at different time points of treatment. Two independent C2 treatment
experiments are shown on 44-hpi schizonts (top) and 42-hpi schizonts (bot-
tom). HRP2 content was measured by ELISA (left), and phosphoantigen con-
centrations were assessed by CD107a test (right) on 3T-cell lines. Results for
representativeT-cell line 384 are shown. (C) Parasite cultures used for panel
B were washed after 6 h of treatment with compound (C2), fresh medium was
added, and supernatants were collected at the indicated times postwash and
tested for both their HRP2 content (left) and their ability to induce V9V2
T-cell degranulation (right). Shown are results from one T-cell line (the
same as that shown in panel B) out of three.
T-Cell Activation by Malaria Phosphoantigens
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activating molecules have all the characteristics of phosphoanti-
gens.
The timing of expression of the DOXP pathway in the apico-
plast (42, 43) is consistent with the observed stage-dependent bio-
activity, as young intracellular stages (ring stages and young tro-
phozoites), in which the apicoplast is poorly active, do not
stimulate V9V2 T cells (44). The exact chemical composition of
parasite stimulants still is uncertain; this is why the quantification
of bioactivity was estimated against an HMBPP reference, which is
the most active phosphoantigen reported to date. Accordingly,
our quantification of soluble bioactivity, expressed as HMBPP
equivalents, may underestimate the actual amount of activators if
some, such as IPP (15), have a lower specific activity. Nevertheless,
our estimates are in accordance with the range of bioactivity (0.1
to 10 nM) measured in supernatants of patient’s neutrophils that
phagocytosed HMBPP-producing bacteria (45), with these
amounts being sufficient to stimulate V9V2 T cells.
Essentially similar temporal patterns of HRP2 and V9V2
T-cell stimulant release into the microenvironment were observed
(Fig. 4A). The bulk of these stimulants seem to be released at the
end of schizogony, when the parasite egresses from the erythro-
cyte. Inhibition of their release by C2 was somewhat less efficient
when parasites were treated at the very late developmental stages
(Fig. 4B, upper). This suggests some leaking of phosphoantigens
before egress, likely due to the increased permeability of iRBCs at
the later stages of schizogony, as suggested by recent observations
showing permeability to immunoglobulins (39). In this case, leak-
iness would preferentially affect low-molecular-mass metabolites,
such as phosphoantigens, while proteins of the size of HRP2 (ap-
proximately 35 kDa) would remain intracellular. Several studies,
including ours, reported stimulation of V9V2 T cells by intact
mature iRBCs cocultivated with V9V2 T cells (1, 5, 9, 14, 30).
We calculated that the amount of stimulants released from as few
as 2% of the iRBCs for the first 20 h of parasite culture already
could be above the threshold of V9V2 T-cell activation. This
suggests that at least part of stimulation by so-called intact iRBCs
occurs through phosphoantigens released from the iRBCs during
cocultivation, either upon artifactual, spontaneous lysis of fragile
iRBCs or rupture of a few older schizonts in the parasite culture.
Nevertheless, the conclusion that the bulk of phosphoantigens are
released upon schizont rupture is substantiated by the fact that
supernatants collected after complete rupture (Fig. 5B) yielded a
10-fold larger amount of bioactivity than supernatants collected
from late developmental stages. As the supernatants were filtered,
the potential contribution of direct activation of V9V2 T cells
by egressed merozoites is excluded.
There was some variability of T-cell line sensitivity to para-
site supernatants, which were used undiluted in most experi-
ments. This differed from the homogeneously maximal activation
conveyed by 100 nM HMBPP, used as a positive control. Variabil-
ity of the response to HMBPP itself was readily unmasked when
using concentrations several logs lower than 100 nM (Fig. 5A), i.e.,
in the range of bioactive phosphoantigens produced by iRBCs.
T-cell line variability, highlighted at low stimulating concentra-
tions, might be explained by donor-dependent variability of cir-
culating V9V2 T cells among PBMC (TCR density, differentia-
tion status, immunologic history, and current infections) or could
reflect variability generated during the in vitro expansion of
V9V2 T cells for 20 to 22 days. Donor-dependent variability of
IFN- production by V9V2 T cells in response to iRBCs has
been reported by d’Ombrain et al. (30).
The experimental conditions used here to investigate the dose
response of V9V2 T cells (105 cells and up to 80 	 104 iRBCs)
allow some extrapolation to clinical situations. In malarial pa-
tients, parasite counts in the range of 80 	 104 iRBCs/ml (0.02%
parasitemia) are frequently observed. Such numbers should re-
lease enough phosphoantigens to distantly stimulate patrolling
V9V2 T cells in vivo. As mature P. falciparum intraerythrocytic
stages are sequestered in the microvasculature (46), schizont burst
occurs in anatomically specific niches. We speculate that the ele-
vated sensitivity of V9V2 T cells allows in vivo activation despite
dilution of phosphoantigens in the extracellular milieu and/or in
the bloodstream. Triggering of V9V2 activation could occur in
the red pulp of the spleen, where V9V2 T cells accumulate and
young intraeythrocytic stages are retained in the slow open circu-
lation (47). It also could occur in microvessels, where mature
iRBC sequestration reduces the blood flow and provokes infil-
trates and inflammation (46).
Exploring these hypotheses is complicated by the inappropri-
ate sensitivity of phosphoantigen detection in patient’s plasma
FIG 5 Measurement of V9V2 T-cell stimulation bioactivity in iRBC super-
natants. Dose-response stimulation of two different T-cell lines with either
HMBPP expressed as a concentration and corresponding quantities in the
assays (A) or supernatant of fully ruptured iRBCs (see Materials and Methods)
and the theoretical corresponding number of contributing iRBCs in the assay,
extrapolated from the dilution factor (B). After stimulation, CD107a surface
expression was assayed. V9V2 T-cell activation obtained with culture super-
natants J, K, and L and uiRBC supernatant are shown. Data represent means

SD from duplicates. Titration of the rupture supernatant with one T-cell
line was calculated at half of the maximum of the percent CD107a V2,
which was obtained after stimulation by both supernatant dilution determined
in panel B and the HMBPP concentration determined in panel A. The HMBPP
equivalent content of the supernatant corresponds to the HMBPP concentra-
tion determined in panel A multiplied by the supernatant dilution factor de-
termined in panel B.
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using mass spectrometry, as the reported limit of quantification
for DMAPP and IPP is in the range of 30 nM (40), i.e., 2 to 3 orders
of magnitude less than that of the V9V2 T cells in bioassay used
here. Our preliminary investigations did not find phosphoantigen
bioactivity in malaria patients’ plasma. This may reflect the short
half-life of phosphoantigens in the peripheral circulation (48) and
does not exclude high concentrations in some tissues.
The results presented here provide a novel framework to un-
derstand the activation of V9V2 T cells during malaria infection
and, more generally, infection by microorganisms lacking butyro-
philin and releasing or secreting activator molecules such as phos-
phoantigens into the microenvironment.
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